Neoleukin Therapeutics

Seattle, United States Founded: 2003 • Age: 23 yrs Listed Acquired By Aquinox Pharma
Therapeutic proteins are developed for immunological disorders using computational methods.

About Neoleukin Therapeutics

Neoleukin Therapeutics is a Healthcare company based in Seattle (United States) founded in 2003, and was acquired by Aquinox Pharma in August 2019. Therapeutic proteins are developed for immunological disorders using computational methods. Neoleukin Therapeutics has raised $4.72 million across 1 funding round from investors including Aquinox Pharma. Its chief executive, as recorded, is Jonathan Drachman. Its focus areas include Life Sciences, Immunotherapy, Small Molecule and Diversified. Its legal entity is AQUINOX PHARMACEUTICALS, INC. Its competitors include Moderna, BeiGene and Biogen; 3 of its 3 listed competitors have raised funding.

Company details

Neoleukin Therapeutics was founded in 2003 and is headquartered in Seattle, United States. Operations focus on the biotechnology sector, where advanced computational approaches are employed to design de novo therapeutic proteins. These proteins target immunological disorders, including cancer and autoimmunity, by mimicking IL-2 signaling without CD25 binding. Enhanced efficacy, reduced toxicity, greater stability, and improved pharmacokinetics are achieved through precise intermolecular interactions.

  • Headquarters Seattle, United States
  • Stage Acquired
  • Sectors
    Healthcare
  • Email
    β€’β€’β€’β€’β€’β€’β€’β€’
  • Website neoleukin.com
  • Social LinkedIn X
  • Acquired by Aquinox Pharma (Aug 2019)
  • Legal Name Aquinox Pharmaceuticals, Inc
Key Metrics

Funding Insights of Neoleukin Therapeutics

Neoleukin Therapeutics has successfully raised a total of $4.72M through 1 strategic funding round. The most recent funding activity was a Series A round of $4.72 million completed in February 2011. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding $4.72M
  • Total Rounds 1
  • Last Round Series A β€” $4.72M
  • First Round $4.72M

    (Feb 2011)

All 1 funding rounds of Neoleukin Therapeutics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.

DateAmountTransaction NameValuationLead InvestorsInvestors
Feb 2011$4.72MSeries A––
–
Valuation history

1 investors in total: 1 institutional.

Investors in Neoleukin Therapeutics

Neoleukin Therapeutics has secured backing from 1 investor. Prominent investors backing the company include Aquinox Pharma.

All
InvestorDescriptionFounded YearDomainLocation
Small molecule targeting PI3K pathway.
2004aqxpharma.comVancouver, Canada
Premium access

Investor details for Neoleukin Therapeutics

The complete investor list, round-by-round participation and investor portfolios require an active premium plan.

  • Complete investor list
  • Round participation
  • Investor portfolios
  • Co-investor network

Verified entity values are shown only after access is granted.

People of Neoleukin Therapeutics

11 people are tracked at Neoleukin Therapeutics (2 in leadership, 8 in board & advisors, 1 in team).

NameRoleGroup
Jonathan Drachman
CEO & PresidentLeadership
Priti Patel
Chief Medical OfficerLeadership
Todd Simpson
Board MemberBoard & advisors
Sarah Noonberg
Board MemberBoard & advisors
Cantey Boyd
Board MemberBoard & advisors
Daniel-Adriano Silva
Scientific AdvisorBoard & advisors
Erin Lavelle
Board MemberBoard & advisors
Martin Babler
Board MemberBoard & advisors
Rohan Palekar
Board MemberBoard & advisors
Kamran Alam
Senior Strategic AdvisorBoard & advisors
James Chesko
Formulation ScientistTeam
Premium access

Complete people profiles for Neoleukin Therapeutics

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

Timeline of Neoleukin Therapeutics

4 dated milestones of Neoleukin Therapeutics across 16 years, from founding to its latest funding, stage changes and deals.

  1. Founded Neoleukin Therapeutics is founded.
  2. Funding First funding round of $4.7M.
  3. IPO Lists on the stock exchange (IPO).
  4. Exit Acquired by Aquinox Pharma.

Competitors of Neoleukin Therapeutics

Neoleukin Therapeutics has 3 listed competitors in our database, 3 of them funded. They include Moderna, BeiGene and Biogen.

Company NameDomainFoundedHQ LocationTotal fundingEmployeesDescription
modernatx.com2010Cambridge, United States$2.78B1,312
mRNA-based therapeutics for diseases including cancer and infections are developed.
beigene.com2010Cambridge, United States$172M1,090
Targeted and immune-oncology drugs for cancer treatment are developed.
biogen.com1978Cambridge, United States$80M1
Therapies for neurodegenerative and immunology disorders are developed.
Premium access

Detailed competitors of Neoleukin Therapeutics

The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.

  • Full competitor set
  • Operating metrics
  • Benchmarks
  • Competitive positioning

Verified entity values are shown only after access is granted.

Top companies in Life Sciences Platforms & Tools

3 companies that operate in the same segment as Neoleukin Therapeutics (Life Sciences Platforms & Tools) in United States, ranked by their profile score on The Company Check.

CompanyDescriptionFoundedLocationTotal fundingRevenueEmployees
Medidata is recognized as a leading provider of SaaS solutions for clinical research.
1999New York, New York, United StatesUSD 41.5 M
AI-based solutions for health management are provided.
2015Dallas, Texas, United StatesUSD 2.8 B1,111
Real-world health data is provided for research and decisions.
2012Menlo Park, California, United StatesUSD 259.16 M
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track β€” from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • βœ“
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • βœ“
    Full access to every database India & global coverage, advanced filters and rich profile details
  • βœ“
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Neoleukin Therapeutics

Premium access

Complete news archive for Neoleukin Therapeutics

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Neoleukin Therapeutics

Neoleukin Therapeutics was founded in 2003 and raised its 1st funding round 8 years after it was founded.

Neoleukin Therapeutics is headquartered in Seattle, United States. It is registered at Seattle, Washington, United States.

Jonathan Drachman is the CEO of Neoleukin Therapeutics, as recorded in our data.

Neoleukin Therapeutics is a funded company, having raised a total of $4.72M across 1 funding round to date. The company's 1st funding round was a Series A of $4.72M, raised on Feb 2011.

Neoleukin Therapeutics was founded in 2003 and is headquartered in Seattle, United States. Operations focus on the biotechnology sector, where advanced computational approaches are employed to design de novo therapeutic proteins. These proteins target immunological disorders, including cancer and autoimmunity, by mimicking IL-2 signaling without CD25 binding. Enhanced efficacy, reduced toxicity, greater stability, and improved pharmacokinetics are achieved through precise intermolecular interactions.

Neoleukin Therapeutics's top competitors include Moderna, BeiGene and Biogen.

Neoleukin Therapeutics has 1 investor. Key investors include Aquinox Pharma.

Neoleukin Therapeutics operates through Aquinox Pharmaceuticals, Inc.

Yes. Neoleukin Therapeutics was acquired by Aquinox Pharma in August 2019.

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available